Literature DB >> 17512587

MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients.

Patrizia Chiusolo1, Giovanni Reddiconto, Giuliana Farina, Alice Mannocci, Alessia Fiorini, Mariangela Palladino, Giuseppe La Torre, Luana Fianchi, Federica Sorà, Luca Laurenti, Giuseppe Leone, Simona Sica.   

Abstract

Recently the influence of polymorphisms of different genes involved in metabolism of chemoterapic agents have been studied especially in childhood acute lymphoblastic leukemia (ALL). We evaluated the influence of C677T and A1298C methylenetetrahydrofolate reductase (MTHFR) polymorphisms on time to relapse and survival and on methotrexate (MTX) toxicity in 82 ALL adult patients. Relapse free survival and event free survival between homozygous wild-type and variant patients in both polymorphisms were not significantly different. However, we observed an association between 677TT variant and survival in a subset of ALL patients homogenously treated with MTX-based maintenance (p=0.02). In the same subgroup we confirmed the role of 677TT variant on toxicity during MTX treatment (p=0.003).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17512587     DOI: 10.1016/j.leukres.2007.03.028

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  16 in total

1.  PharmGKB summary: methotrexate pathway.

Authors:  Torben S Mikkelsen; Caroline F Thorn; Jun J Yang; Cornelia M Ulrich; Deborah French; Gianluigi Zaza; Henry M Dunnenberger; Sharon Marsh; Howard L McLeod; Kathy Giacomini; Mara L Becker; Roger Gaedigk; James Steven Leeder; Leo Kager; Mary V Relling; William Evans; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-10       Impact factor: 2.089

2.  Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia.

Authors:  Noha M El-Khodary; Sahar M El-Haggar; Manal A Eid; Emad N Ebeid
Journal:  Med Oncol       Date:  2011-06-05       Impact factor: 3.064

3.  Alterations in the expression pattern of MTHFR, DHFR, TYMS, and SLC19A1 genes after treatment of laryngeal cancer cells with high and low doses of methotrexate.

Authors:  Ana Lívia Silva Galbiatti; Rodrigo Castro; Heloisa Cristina Caldas; João Armando Padovani; Erika Cristina Pavarino; Eny Maria Goloni-Bertollo
Journal:  Tumour Biol       Date:  2013-07-10

Review 4.  Gene polymorphisms in the folate metabolism and their association with MTX-related adverse events in the treatment of ALL.

Authors:  Yang Chen; Zuojun Shen
Journal:  Tumour Biol       Date:  2015-05-30

5.  Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis.

Authors:  Lin Yang; Xin Hu; Luhang Xu
Journal:  Tumour Biol       Date:  2012-04-20

Review 6.  Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy.

Authors:  Lin Mei; Evelena P Ontiveros; Elizabeth A Griffiths; James E Thompson; Eunice S Wang; Meir Wetzler
Journal:  Blood Rev       Date:  2015-01-10       Impact factor: 8.250

7.  Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype.

Authors:  Kyoko Sugimoto; Makoto Murata; Makoto Onizuka; Yoshihiro Inamoto; Seitaro Terakura; Yachiyo Kuwatsuka; Taku Oba; Koichi Miyamura; Yoshihisa Kodera; Tomoki Naoe
Journal:  Int J Hematol       Date:  2008-03-26       Impact factor: 2.490

8.  Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival.

Authors:  Alessia Ongaro; Monica De Mattei; Matteo Giovanni Della Porta; GianMatteo Rigolin; Cristina Ambrosio; Francesco Di Raimondo; Agnese Pellati; Federica Francesca Masieri; Angelo Caruso; Linda Catozzi; Donato Gemmati
Journal:  Haematologica       Date:  2009-07-31       Impact factor: 9.941

Review 9.  Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?

Authors:  Sunitha Kodidela; Pradhan Suresh Chandra; Biswajit Dubashi
Journal:  Eur J Clin Pharmacol       Date:  2013-12-27       Impact factor: 2.953

10.  Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and promoter methylation in cervical oncogenic lesions and cancer.

Authors:  Anca Botezatu; Demetra Socolov; Iulia V Iancu; Irina Huica; Adriana Plesa; Carmen Ungureanu; Gabriela Anton
Journal:  J Cell Mol Med       Date:  2013-02-28       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.